Aptevo Therapeutics (NASDAQ:APVO) Shares Down 5.5% – What’s Next?

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares traded down 5.5% during mid-day trading on Monday . The stock traded as low as $4.61 and last traded at $4.68. 78,302 shares traded hands during mid-day trading, an increase of 3% from the average session volume of 75,708 shares. The stock had previously closed at $4.95.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen assumed coverage on shares of Aptevo Therapeutics in a research note on Sunday, May 18th. They issued a “sell” rating on the stock.

Aptevo Therapeutics Stock Down 5.5%

The company’s 50 day moving average price is $12.25 and its 200-day moving average price is $511.86.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($87.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($84.20) by ($3.60). Research analysts expect that Aptevo Therapeutics Inc. will post -15.84 earnings per share for the current fiscal year.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.